Compare Natera Inc. Common Stock (NTRA) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Victoria's Secret & Co — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Victoria's Secret & Co trades at $86.8 (market cap $7.08B). The key difference: Natera Inc. Common Stock is far larger — about 8.1× Victoria's Secret & Co's market cap, and Victoria's Secret & Co is more actively traded (1,247,026 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Victoria's Secret & Co for 34 Days on average.
| NTRA | VSXY | |
|---|---|---|
Market Cap | $57.03B | $7.08B |
Volume | 1,131,157 | 1,247,026 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $99.97 |
52-Week Low | $179.42 | $30.19 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $56.18B | $9.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Victoria's Secret (VSXY) trades at $88.39, down 0.23% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy, though valuation remains elevated at P/E 19.83 and P/B 7.16.
The outlook appears positive with 60% analyst buy ratings and projected net income growth to $378M in 2026. Key opportunities include international expansion and margin improvement, while risks involve rich valuation, rising costs, and competitive pressures in retail apparel. The stock trades near consensus target of $86.80 with upside potential to $101.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
